Education
About Us
Working with TipRanks
Follow Us
Evaxion Biotech (EVAX)
NASDAQ:EVAX
EVAX Stock Chart & Stats
$5.26
-$0.02(-2.40%)
At close: 4:00 PM EST
$5.26
-$0.02(-2.40%)
Day’s Range― - ―
52-Week Range$1.20 - $12.15
Previous CloseN/A
Volume99.85K
Average Volume (3M)536.39K
Market Cap
$32.91M
Enterprise ValueN/A
Total Cash (Recent Filing)$10.57M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Apr 07, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding6,316,572
10 Day Avg. Volume152,874
30 Day Avg. Volume536,395
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)-54.94
Price to Sales (P/S)27.14
P/FCF Ratio-7.01
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$12.33Price Target Upside134.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AI-Driven PlatformPIONEER predicts clinically relevant neoantigens with high accuracy, suggesting it could become a field-leading tool for designing novel therapies.
Clinical DataPromising POC Phase 2 data in melanoma shows both a durable clinical benefit and sustained immune response at the 2-year cutoff.
Strategic PartnershipsMerck exercised its option on a preclinical stage infectious disease vaccine candidate, resulting in a cash payment of $7.5MN to Evaxion and eligibility for milestone payments with a potential value of up to $592MN.
Bears Say
Business ModelThe business model focused on developing vaccines through Phase 1/2 trials and then partnering or out-licensing the assets poses a valuation challenge, as the model is royalty-based and excludes milestone revenue.
Financial PerformanceThe company reported no revenues with a net loss of $0.02 per diluted share.
RisksRisks include partnership, technology, clinical, regulatory, commercial, legal, intellectual property, and competition.
Evaxion Biotech News
EVAX FAQ
What was Evaxion Biotech’s price range in the past 12 months?
Evaxion Biotech lowest stock price was $1.20 and its highest was $12.15 in the past 12 months.
What is Evaxion Biotech’s market cap?
Evaxion Biotech’s market cap is $32.91M.
When is Evaxion Biotech’s upcoming earnings report date?
Evaxion Biotech’s upcoming earnings report date is Apr 07, 2026 which is in 138 days.
How were Evaxion Biotech’s earnings last quarter?
Evaxion Biotech released its earnings results on Nov 06, 2025. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.01 by $0.02.
Is Evaxion Biotech overvalued?
According to Wall Street analysts Evaxion Biotech’s price is currently Undervalued.
Does Evaxion Biotech pay dividends?
Evaxion Biotech does not currently pay dividends.
What is Evaxion Biotech’s EPS estimate?
Evaxion Biotech’s EPS estimate is -0.01.
How many shares outstanding does Evaxion Biotech have?
Evaxion Biotech has 6,316,572 shares outstanding.
What happened to Evaxion Biotech’s price movement after its last earnings report?
Evaxion Biotech reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.01. Following the earnings report the stock price went up 10.601%.
Which hedge fund is a major shareholder of Evaxion Biotech?
Currently, no hedge funds are holding shares in EVAX
Evaxion Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.33 (134.41% Upside)
$12.33 (134.41% Upside)
Blogger Sentiment
Bullish
EVAX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 10.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Company Description
Evaxion Biotech
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
EVAX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance and significant advancements in R&D, including a transformative deal with MSD and promising clinical data for EVX-01. However, market uncertainties and extended evaluation periods for deals, like EVX-B2, present challenges. Overall, the achievements and financial stability significantly outweigh the challenges.View all EVAX earnings summariesEVAX Stock 12 Month Forecast
Average Price Target
$12.33
▲(134.41% Upside)
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
1.64% Other Institutional Investors
98.35% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---